Modelling the resource implications of managing adults with Fabry disease in Italy

European Journal of Clinical Investigation

Volumn 41, Issue 7, 2011, Pages 710-718

  Guest, Julian F ^a,b   Concolino, Daniela ^c   di Vito, Raffaele ^d   Feliciani, Claudio ^e   Parini, Rossella ^f   Zampetti, Anna ^e  

^a CATALYST Health Economics Consultants   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d Ospedale G Bernabeo   (Italy)

^e FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^f SAN GERARDO HOSPITAL   (Italy)

Author keywords

Agalsidase alfa; Agalsidase beta; Fabrazyme; Fabry disease; Italy; Replagal; Servizio Sanitario Nazionale

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA;

ADULT; ADULT DISEASE; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HOME CARE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADULT; ALPHA-GALACTOSIDASE; DECISION SUPPORT TECHNIQUES; DRUG COSTS; FABRY DISEASE; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; ISOENZYMES; ITALY; MALE; MODELS, ECONOMETRIC; SENSITIVITY AND SPECIFICITY;

EID: 79958722345     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02458.x     Document Type: Article

References (33)

1. Peters FPJ, Vermeulen A, Kho TL. Anderson-Fabry's disease: α-galactosidase deficiency. Lancet 2001;357:138-40.
2. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C et al. Fabry disease defined: baseline clinical manifestations of 366 patients in FOS - the Fabry Outcome Survey. Eur J Clin Invest, 2004;34:236-42.
3. Ries M, Ramaswami U, Parini R, Lindblad B, Whybra C, Willers I et al. The early clinical phenotype of Fabry disease: a study of 35 European children. Eur J Pediatr 2003;162:767-72.
4. Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M et al. Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet 2009;46:548-52.
5. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 2001:pp. 37-74.
6. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54.
7. Pastores GM, Thadhani R. Advances in the management of Anderson-Fabry disease: enzyme replacement therapy. Expert Opin Biol Ther 2002;2:1-9.
8. Whybra C, Miebach E, Mengel E, Gal A, Baron K, Beck M et al. A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med. 2009;11:441-9.
9. West M, Nicholls K, Mehta A, Clarke JT, Steiner R, Beck M et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009;20:1132-9.
10. Feriozzi S, Schwarting A, Sunder-Plassmann G, West M, Cybulla M; International Fabry Outcome Survey Investigators. Agalsidase alfa slows the decline in renal function in patients with Fabry disease. Am J Nephrol 2009;29:353-61.
11. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ et al. Sustained, long-term renal stabilization after 54months of agalsidase beta therapy in patients with Fabry disease. Am Soc Nephrol 2007;18:1547-57.
12. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007;146:77-86.
13. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S et al. Safety and efficacy of recombinant human α-galactosidase A replacement in Fabry disease. N Engl J Med 2001;345:9-16.
14. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 2005;21:345-54.
15. Linthorst GE, Vedder AC, Ormel EE, Aerts JM, Hollak CE. Home treatment for Fabry disease: practice guidelines based on 3years experience in The Netherlands. Nephrol Dial Transplant 2006;21:355-60.
16. Milligan A, Hughes D, Goodwin S, Richfield L, Mehta A. Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs 2006;15:330-3.
17. European Medicines Agency reviews treatment recommendations for Fabrazyme. European Medicines Agency. 22 October 2010; EMA/CHMP/654389/2010. Available at:. Accessed on 11 November 2010.
18. ®). Available at:. Accessed on 11 November 2010.
19. France G, Taroni F, Donatini A. The Italian health-care system. Health Econ 2005;14:S187-202.
20. OECD Health Data 2008. Available online at.
21. Lee K, Jin X, Zhang K, Copertino L, Andrews L, Baker-Malcolm J et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 2003;13:305-13.
22. Sakuraba H, Murata-Ohsawa M, Kawashima I, Tajima Y, Kotani M, Ohshima T et al. Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J Hum Genet 2005;51:180-8.
23. Pastores GM, Thadhani R. Enzyme-replacement therapy for Anderson-Fabry disease. Lancet 2001;358:601-3.
24. Bengtsson BA, Johansson JO, Hollak C, Linthorst G, Feldt Rasmussen U. Enzyme replacement in Anderson-Fabry disease. Lancet 2003;361:352.
25. Hopkin RJ, Bissler J, Grabowski GA. Comparative evaluation of alphagalactosidase A infusions for treatment of Fabry disease. Genet Med 2003;5:144-53.
26. Desnick RJ. Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval. Expert Opin Biol Ther 2004;4:1167-76.
27. Mignani R, Cagnoli L. Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications. J Nephrol 2004;17:354-63.
28. Lidove O, Joly D, Barbey F, Bekri S, Alexandra JF, Peigne V et al. Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract 2007;61:293-302.
29. Lidove O, West M, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE et al. Effects of enzyme replacement therapy in Fabry disease - A comprehensive review of the medical literature. Genetics in Medicine 2010;12:668-79.
30. Drummond M, Evans B, LeLorier J, Karakiewicz P, Martin D, Tugwell P et al. Evidence and values: requirements for public reimbursement of drugs for rare diseases - a case study in oncology. Can J Clin Pharmacol 2009;16: e273-81; discussion e282-4. Epub 2009.
31. Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-9.
32. Bodensteiner D, Scott RC, Sims KB, Shepherd GM, Cintron RD, Germain DP. Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme. Genet Med 2008;10:353-8.
33. Guest JF, Jenssen T, Houge G, Aaseboe W, Tøndel C, Svarstad E. Modelling the resource implications of managing adults with Fabry disease in Norway favours home infusion. Eur J Clin Invest 2010;40:1104-12.